Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1-positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001,-010,-024, and-042-MedSci.cn

Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1-positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001,-010,-024, and-042

Mansfield, AS; Herbst, RS; CastroJr, G; Hui, R; Peled, N; Kim, DW; Novello, S; Satouchi, M; Wu, YL; Garon, EB; Reck, M; Robinson, AG; Samkari, A; Piperdi, B; Ebiana, V; Lin, J; Mok, TSK

ANNALS OF ONCOLOGY, 2019; 30 (): 604

科室
- - 订阅+
  - 更多科室
工具
服务